Results 91 to 100 of about 3,596 (160)

Development and Validation of an Ion-Pair Reverse-Phase High-Performance Liquid Chromatography-Electrospray Ionization Mass Spectrometry Method for Determination of Purity of Nusinersen for Quality Control of Drug Substance or Drug Product. [PDF]

Int J Mol Sci
Samoilov M, Zubareva E, Degterev M.
europepmc   +1 more source

Cognitive and neurodevelopmental outcomes in spinal muscular atrophy: a scoping review. [PDF]

Front Cell Neurosci
Gnazzo M, Pisanò G, Baldini V, Giordani S, Caiazza L, Piccolo B, Turco E, Esposito S, Pera MC.   +8 more
europepmc   +1 more source

Unbiased bioinformatic and clinical analysis identifies glial fibrillary acidic protein as a potential biomarker in spinal muscular atrophy. [PDF]

Brain Commun
Soares de Oliveira KL, Weber AC, Becker MM, Magalhães JSA, de Albuquerque ALA, Chadanowicz JK, Giudicelli GC, Rohden F, Zimmer ER, Kowalski TW, Siebert M, Costa MCM, Saute JA.   +12 more
europepmc   +1 more source

Delayed diagnosis and genetic testing in spinal muscular atrophy: a case series. [PDF]

Ann Med
Guo X, Luo Y, Li M, Li C, Chang Z, Zhu S, Wang Q, Huang Y.   +7 more
europepmc   +1 more source

Nusinersen Use in Spinal Muscular Atrophy [PDF]

Pediatrics, 2019
openaire   +2 more sources

Impact of Intermittent Positive Pressure Breathing on Thoracic Growth in Children With Type 1 Spinal Muscular Atrophy. [PDF]

Pediatr Pulmonol
Thébault C, Denamur S, Thomas G, Barzic A, Schwartz E, Dupuis M, Nougues MC, Isapof A, Aubertin G, Taytard J.   +9 more
europepmc   +1 more source

Serum p-tau181 and p-tau217 levels in adolescents and adults with 5q spinal muscular atrophy. [PDF]

J Neurol
Stapf CD, Uzelac Z, Iterbeke L, Guthknecht A, Barba L, Strube D, Kölsch A, Kleeberg K, Kendzierski T, Roos A, Steinacker P, Abu-Rumeileh S, Claeys KG, Weishaupt J, Mensch A, Otto M.   +15 more
europepmc   +1 more source

Administration practice and adherence of nusinersen in adults with 5q-spinal muscular atrophy in China: an ambispective multicenter study. [PDF]

BMC Neurol
Yao X, Dai Y, Zhu W, Zhao Y, Shang H, Meng Q, Liu Y, Yu L, Hong D, Chen J, Shen L, Chen W, Chen K, Zhang L, Mai M, Cui L.   +15 more
europepmc   +1 more source

Nusinersen effectiveness and safety in children with type II/III 5q-spinal muscular atrophy: Second interim analysis from a Chinese disease registry. [PDF]

Chin Med J (Engl)
Wang X, Yao X, Peng J, Luo R, Lu H, Liang J, Jin R, Wu L, Zhong J, Yang L, Wu J, Hong S, Ruan Y, Shen T, Zhang X, Mao S, Hu J, Wang H, Sun D, Tao Z, Yang G, Bian G, Lyu J, Zhang L, Zhu J, Wang Y.   +25 more
europepmc   +1 more source

Longitudinal motor function and biomarker correlates in treated adult spinal muscular atrophy: a single-center cohort study. [PDF]

Front Neurol
Yano C, Ando M, Yoshimura A, Higuchi Y, Noda Y, Yuan JH, Nakamura T, Hobara T, Nagatomo R, Kojima F, Yuji M, Hiramatsu Y, Nozuma S, Hashiguchi A, Sakiyama Y, Takashima H.   +15 more
europepmc   +1 more source